Table 2. Clinical and functional outcome from NAVF stroke patients.
| Total N = 129 (%) | FemaleN= 77 (%) | MaleN= 52 (%) | p | |
|---|---|---|---|---|
| NIHSS score at discharge | ||||
| 0–5 | 27 (21.1) | 16 (21.1) | 11 (21.2) | 0.90 |
| 6–11 | 28 (21.7) | 18 (23.4) | 10 (19.2) | 0.57 |
| ≥12 | 74 (57.4) | 43 (55.8) | 31 (59.6) | 0.67 |
| Bad outcome (mRs ≥3) | ||||
| Discharge | 92 (71.4) | 59 (76.6) | 33 (63.5) | 0.10 |
| 6 months | 90 (69.8) | 57 (74) | 33 (63.5) | 0.20 |
| 12 months | 89 (69.7) | 57 (74) | 32 (61.5) | 0.13 |
| Oral Anticoagulation | 77 (59.7) | 43 (55.8) | 34 (65.4) | 0.28 |
| Recurrence | 28 (21.7) | 16 (20.8) | 12 (23.1) | 0.46 |
| Mortality (end of period) | 47 (36.4) | 31 (40.3) | 16 (30.8) | 0.18 |
mRs: modified Rankin score.